Aurinia Pharmaceuticals Inc. (AUPH)
NASDAQ: AUPH · Real-Time Price · USD
8.89
-0.21 (-2.30%)
Dec 3, 2024, 12:09 PM EST - Market open
Aurinia Pharmaceuticals Employees
Aurinia Pharmaceuticals had 300 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
300
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$734,537
Profits / Employee
-$75,173
Market Cap
1.27B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Pediatrix Medical Group | 5,450 |
Tilray Brands | 2,650 |
Embecta | 2,200 |
Artivion | 1,500 |
Phreesia | 1,438 |
Establishment Labs Holdings | 908 |
CareDx | 643 |
BioLife Solutions | 414 |
AUPH News
- 14 days ago - Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis - Business Wire
- 18 days ago - Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024 - Business Wire
- 19 days ago - Aurinia to Participate in Jefferies London Healthcare Conference - Business Wire
- 24 days ago - Aurinia Pharmaceuticals: A Potential Buyout Looms On The Horizon - Seeking Alpha
- 26 days ago - Aurinia Pharmaceuticals, Inc. (AUPH) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 26 days ago - Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth - Business Wire
- 26 days ago - Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Development - Business Wire
- 4 weeks ago - Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024 - Business Wire